Effects of CD133 expression on chemotherapy and drug sensitivity of adenoid cystic carcinoma

Zhou,Lian; Sun,Ying; Ye,Guo; Zhao,Yanguang; Wu,Jian

doi:10.3892/mmr.2021.12534

Effects of CD133 expression on chemotherapy and drug sensitivity of adenoid cystic carcinoma

Authors:
- Lian Zhou
- Ying Sun
- Guo Ye
- Yanguang Zhao
- Jian Wu
View Affiliations

Affiliations: Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing 400030, P.R. China
Published online on: November 17, 2021 https://doi.org/10.3892/mmr.2021.12534
Article Number: 18
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The cellular resistance of tumors is a major obstacle for successful tumor therapy. Cluster of differentiation (CD)133 plays an important role in the regulation of drug resistance in gastric and colon cancers. However, its effect on chemotherapeutic sensitivity in adenoid cystic carcinoma (ACC) has not been fully explored. The present study discussed the specific role of CD133 in ACC drug‑resistant sensitive cells. KOA‑1 cells were treated with 5‑fluorouracil (5‑FU) and pingyangmycin (PYM) to form drug‑resistant cell lines. A Cell Counting Kit‑8 assay was used to detect the cell survival rate. Cell invasion was measured using a Transwell assay. The expression levels of CD133 were detected by reverse transcription‑quantitative (RT‑q) PCR. The expression levels of drug‑resistant mRNAs and proteins were detected by RT‑qPCR and immunofluorescence analyses, respectively. The CD133 were inhibited by small interfering RNA technology. The survival rate and invasive ability of KOA‑1 cells were increased following the induction of drug resistance. The expression levels of CD133, multidrug resistance protein (MDR)1 and multidrug resistance‑associated protein (MRP)1 were significantly increased in drug‑resistant cell lines. Knockdown of CD133 expression in the resistant cell lines, KOA‑1/5‑FU and KOA‑1/PYM, decreased the survival rate and invasive ability. The expression levels of MDR1 and MRP1 were also significantly decreased. Knockdown of CD133 expression in ACC drug‑resistant cells could inhibit the viability and invasion of tumors and enhance the sensitivity of drug‑resistant cells to chemotherapeutic drugs.

View Figures

View References

1	Bradley PJ: Adenoid cystic carcinoma evaluation and management: Progress with optimism! Curr Opin Otolaryngol Head Neck Surg. 25:147–153. 2017. View Article : Google Scholar : PubMed/NCBI
2	Coca-Pelaz A, Rodrigo JP, Bradley PJ, Vander Poorten V, Triantafyllou A, Hunt JL, Strojan P, Rinaldo A, Haigentz M Jr, Takes RP, et al: Adenoid cystic carcinoma of the head and neck - An update. Oral Oncol. 51:652–661. 2015. View Article : Google Scholar : PubMed/NCBI
3	Castelnuovo P and Turri-Zanoni M: Adenoid cystic carcinoma. Adv Otorhinolaryngol. 84:197–209. 2020.PubMed/NCBI
4	Gao M, Hao Y, Huang MX, Ma DQ, Luo HY, Gao Y, Peng X and Yu GY: Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma. Int J Oral Maxillofac Implants. 42:923–928. 2013. View Article : Google Scholar : PubMed/NCBI
5	Ma B, Liang LZ, Liao GQ, Liang YJ, Liu HC, Zheng GS and Su YX: Inhibition of autophagy enhances cisplatin cytotoxicity in human adenoid cystic carcinoma cells of salivary glands. J Oral Pathol Med. 42:774–780. 2013. View Article : Google Scholar : PubMed/NCBI
6	Yu J, Tang Z, Gong W, Zhang M and Quan Z: Isolation and identification of tumor-initiating cell properties in human gallbladder cancer cell lines using the marker cluster of differentiation 133. Oncol Lett. 14:7111–7120. 2017.PubMed/NCBI
7	Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ and Heeschen C: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 1:313–323. 2007. View Article : Google Scholar : PubMed/NCBI
8	Li C, Wang C, Xing Y, Zhen J and Ai Z: CD133 promotes gallbladder carcinoma cell migration through activating Akt phosphorylation. Oncotarget. 7:17751–17759. 2016. View Article : Google Scholar : PubMed/NCBI
9	Manoranjan B, Chokshi C, Venugopal C, Subapanditha M, Savage N, Tatari N, Provias JP, Murty NK, Moffat J, Doble BW, et al: A CD133-AKT-Wnt signaling axis drives glioblastoma brain tumor-initiating cells. Oncogene. 39:1590–1599. 2020. View Article : Google Scholar : PubMed/NCBI
10	Lu R, Zhao G, Yang Y, Jiang Z, Cai J and Hu H: Inhibition of CD133 overcomes cisplatin resistance through inhibiting PI3K/AKT/mTOR signaling pathway and autophagy in CD133-positive gastric cancer cells. Technol Cancer Res Treat. Jan 1–2019.(Epub ahead of print). doi: 10.1177/1533033819864311. View Article : Google Scholar
11	Fayi MA, Alamri A and Rajagopalan P: IOX-101 Reverses drug resistance through suppression of Akt/mTOR/NF-κB signaling in cancer stem cell-like, sphere-forming NSCLC cell. Oncol Res. 28:177–189. 2020. View Article : Google Scholar : PubMed/NCBI
12	Yuan Z, Liang X, Zhan Y, Wang Z, Xu J, Qiu Y, Wang J, Cao Y, Le VM, Ly HT, et al: Targeting CD133 reverses drug-resistance via the AKT/NF-κB/MDR1 pathway in colorectal cancer. Br J Cancer. 122:1342–1353. 2020. View Article : Google Scholar : PubMed/NCBI
13	Panaccione A, Zhang Y, Ryan M, Moskaluk CA, Anderson KS, Yarbrough WG and Ivanov SV: MYB fusions and CD markers as tools for authentication and purification of cancer stem cells from salivary adenoid cystic carcinoma. Stem Cell Res (Amst). 21:160–166. 2017. View Article : Google Scholar : PubMed/NCBI
14	Wang SS, Gao XL, Liu X, Gao SY, Fan YL, Jiang YP, Ma XR, Jiang J, Feng H, Chen QM, et al: CD133⁺ cancer stem-like cells promote migration and invasion of salivary adenoid cystic carcinoma by inducing vasculogenic mimicry formation. Oncotarget. 7:29051–29062. 2016. View Article : Google Scholar : PubMed/NCBI
15	Panayotopoulou EG, Müller AK, Börries M, Busch H, Hu G and Lev S: Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells. Oncotarget. 8:45088–45104. 2017. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Cherifi F, Rambeau A, Johnson A, Florescu C, Géry B, Babin E and Thariat J: Systemic treatments of metastatic or locally recurrent adenoid cystic carcinoma of the head and neck, a systematic review. Bull Cancer. 106:923–938. 2019.(In French). View Article : Google Scholar : PubMed/NCBI
18	Qi W, Guo J, Wu S, Su B, Zhang L, Pan J and Zhang J: Synergistic effect of nanosecond pulsed electric field combined with low-dose of pingyangmycin on salivary adenoid cystic carcinoma. Oncol Rep. 31:2220–2228. 2014. View Article : Google Scholar : PubMed/NCBI
19	Vasan N, Baselga J and Hyman DM: A view on drug resistance in cancer. Nature. 575:299–309. 2019. View Article : Google Scholar : PubMed/NCBI
20	Bi CL, Fang JS, Chen FH, Wang YJ and Wu J: Chemoresistance of CD133(+) tumor stem cells from human brain glioma. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 32:568–573. 2007.(In Chinese). PubMed/NCBI
21	Attia S, Atwan N, Arafa M and Shahin RA: Expression of CD133 as a cancer stem cell marker in invasive gastric carcinoma. Pathologica. 111:18–23. 2019. View Article : Google Scholar : PubMed/NCBI
22	Barzegar Behrooz A, Syahir A and Ahmad S: CD133: Beyond a cancer stem cell biomarker. J Drug Target. 27:257–269. 2019. View Article : Google Scholar : PubMed/NCBI
23	Aghajani M, Mansoori B, Mohammadi A, Asadzadeh Z and Baradaran B: New emerging roles of CD133 in cancer stem cell: Signaling pathway and miRNA regulation. J Cell Physiol. 234:21642–21661. 2019. View Article : Google Scholar : PubMed/NCBI
24	Jia Q, Zhang X, Deng T and Gao J: Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells. Cell Reprogram. 15:143–150. 2013. View Article : Google Scholar : PubMed/NCBI
25	Sarvi S, Mackinnon AC, Avlonitis N, Bradley M, Rintoul RC, Rassl DM, Wang W, Forbes SJ, Gregory CD and Sethi T: CD133⁺ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res. 74:1554–1565. 2014. View Article : Google Scholar : PubMed/NCBI
26	van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, van der Pol MA, Waisfisz Q, Ossenkoppele GJ and Schuurhuis GJ: High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 11:6520–6527. 2005. View Article : Google Scholar : PubMed/NCBI
27	Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, et al: Highly tumorigenic lung cancer CD133⁺ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA. 106:16281–16286. 2009. View Article : Google Scholar : PubMed/NCBI
28	Lee TK, Castilho A, Cheung VC, Tang KH, Ma S and Ng IO: CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell. 9:50–63. 2011. View Article : Google Scholar : PubMed/NCBI
29	Kong FB, Deng QM, Deng HQ, Dong CC, Li L, He CG, Wang XT, Xu S and Mai W: Siva 1 regulates multidrug resistance of gastric cancer by targeting MDR1 and MRP1 via the NF-κB pathway. Mol Med Rep. 22:1558–1566. 2020. View Article : Google Scholar : PubMed/NCBI